Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (2 selected)

Type

Guidance programme (11 selected)

Guidance programme

Showing 101 to 125 of 746

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and overTA893
FibroScan for assessing liver fibrosis and cirrhosis outside secondary and specialist careDG48
Daratumumab with bortezomib and dexamethasone for previously treated multiple myelomaTA897
Esketamine for treating major depressive disorder in adults at imminent risk of suicide (terminated appraisal)TA899
Intraoperative electron beam radiotherapy for locally advanced and locally recurrent colorectal cancerIPG763
Transperineal biopsy for diagnosing prostate cancerDG54
Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemiaTA891
Mosunetuzumab for treating relapsed or refractory follicular lymphomaTA892
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcersDG52
MRI fusion biopsy systems for diagnosing prostate cancerDG53
Intramuscular diaphragm stimulation for ventilator-dependent chronic respiratory failure from high spinal cord injuriesIPG762
Risankizumab for previously treated moderately to severely active Crohn's diseaseTA888
Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma (terminated appraisal)TA889
Difelikefalin for treating pruritus in people having haemodialysisTA890
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Tezepelumab for treating severe asthmaTA880
Lumasiran for treating primary hyperoxaluria type 1HST25
Onasemnogene abeparvovec for treating spinal muscular atrophyHST15
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiencyHST26
Onasemnogene abeparvovec for treating presymptomatic spinal muscular atrophyHST24

Results per page

  1. 10
  2. 25
  3. 50
  4. All